The role of somatostatin analogues in the treatment of advanced malignant thymomas: case report and review of the literature
Authors:
Open Access
- 1 January 2011
- journal article
- case report
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 84 (997) , e7-e10
Abstract
Thymomas are the most common tumours of the anterior mediastinum; their clinical course is often complicated by accompanying autoimmune and paraneoplastic syndromes. Advanced malignant thymoma is particularly challenging to manage owing to the lack of evidence from randomised trials to guide treatment. Combination first-line chemotherapy has been trialled in several small studies and has been reported to produce a 50–80% response with platinum-containing regimes. Progression following first-line chemotherapy is difficult to manage as most of these patients maintain a good performance status and demand further active palliative treatment. There is no standard second-line treatment. We report a good clinical and radiological response to third-line palliative octreotide therapy in a patient who had a positive octreotide scan.Keywords
This publication has 12 references indexed in Scilit:
- Treatment of malignant thymomaCurrent Opinion in Oncology, 2005
- Somatostatin analogs and prednisone in advanced refractory thymic tumorsCancer, 2002
- Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.2001
- Somatostatin Receptor Subtypes in Human Thymoma and Inhibition of Cell Proliferation by Octreotide in VitroThe Journal of Clinical Endocrinology & Metabolism, 2000
- Thymoma: State of the ArtJournal of Clinical Oncology, 1999
- Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.Journal of Clinical Oncology, 1997
- Intensive Chemotherapy with Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide and Granulocyte Colony-stimulating Factor for Advanced Thymona or Thymic Cancer: Preliminary ResultsJapanese Journal of Clinical Oncology, 1995
- Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.Journal of Clinical Oncology, 1994
- Chemotherapy for invasive thymoma. A 13-year experienceCancer, 1991
- Follow-up study of thymomas with special reference to their clinical stagesCancer, 1981